We discuss the clinical presentation and management of a 36-year-old woman presenting with a 12-year history of recurrent hydatid disease, a disease caused by Echinococcus granulosus and other Echinococcal species, which is rarely seen in the contiguous United States. She has had multiple procedures since her diagnosis in 2005 and is still closely being followed for possible disease recurrence.
Nafazatrom was tested against a variety of human malignancies with the human tumor stem cell assay at one or more of the following concentrations: 1, 10, 25, and 100/xg/ml • 1 h or 0.05, 0.5, or 5/~g/ml by continuous exposure. Major (__> 70%) inhibition was noted in 7/52 adenocarcinomas, in 0/9 squamous carcinomas, and 1/17 other malignancies. Intermediate levels of inhibition (50 to 69%) were noted in 7/52, 4/9, and 6/17 of these respective subtypes. No clear trend toward superiority of any dose-schedule was noted. Since nafazatrom has proven non-toxic in our nearly completed Phase I study, and since this study suggests activity against several human cancers, Phase II level testing is warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.